THREE-YEAR OUTCOMES IN A RANDOMIZED SINGLE-BLIND CONTROLLED TRIAL OF INTRAVITREAL RANIBIZUMAB AND ORAL SUPPLEMENTATION WITH DOCOSAHEXAENOIC ACID AND ANTIOXIDANTS FOR DIABETIC MACULAR EDEMA

PURPOSE: To report 3-year results of a randomized single-blind controlled trial of intravitreal ranibizumab combined with oral docosahexaenoic acid (DHA) supplementation versus ranibizumab alone in patients with diabetic macular edema. METHODS: There were 26 patients (31 eyes) in the DHA group and 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Lafuente, María, Ortín, Lourdes, Argente, María, Guindo, José L., López-Bernal, María D., López-Román, Francisco J., Domingo, Joan Carles, Lajara, Jerónimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Retina 2019
Materias:
Original Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6553973/
https://www.ncbi.nlm.nih.gov/pubmed/29474306
http://dx.doi.org/10.1097/IAE.0000000000002114

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6553973/
https://www.ncbi.nlm.nih.gov/pubmed/29474306
http://dx.doi.org/10.1097/IAE.0000000000002114

Ejemplares similares